Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Italian Stock Exchange  >  DiaSorin S.p.A.    DIA   IT0003492391

DIASORIN S.P.A.

(DIA)
  Report
Real-time Estimate Quote. Real-time Estimate Tradegate - 07/03 08:23:36 am
170.95 EUR   -0.20%
06/15DIASORIN S.P.A. : Ex-dividend day for final dividend
FA
06/10DIASORIN S P A : Shareholders' Meeting June 10, 2020
PU
06/10DIASORIN S.P.A. : Proxy Statments
CO
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

DiaSorin S p A : Fatturato in crescita e redditività confermata nel primo trimestre 2020 per il Gruppo DiaSorin nonostante l'impatto della pandemia

share with twitter share with LinkedIn share with facebook
05/13/2020 | 07:25am EDT

DIASORIN GROUP REPORTS REVENUE GROWTH AND CONFIRMED PROFITABILITY IN THE FIRST

QUARTER 2020 DESPITE THE IMPACT OF THE PANDEMIC

Q1 2020 RESULTS

REVENUES: € 174.6 million, +2.3% (+1.7% at CER). Growth in revenues compared to Q1'19, despite volumes decline in routine tests in the hardest-hit countries by COVID-19, in particular China, Italy and United States.

Strong performance of molecular diagnostics sales in Q1'20 (+47.9% at CER), also driven by the launch of the rapid Coronavirus test in Europe and in the U.S. at the end of March and by the flu tests sales increase, mainly in the U.S. market.

EBITDA: € 64.5 million, -4.5% (-3.7%at CER), equal to 36.9% of Group revenues.

It is worth mentioning how, in Q1'20, the Group recorded a one-off cost of € 3.3 million related to the South African facility. This prevents a comparison on a like-for-like basis with Q1'19. Net of this one-off cost, EBITDA would have been

  • 67.8 million, equal to 38.8% of Group revenues (39.5% at CER, +1.6% vs. Q1'19).

EBIT: € 49.4 million, -6.7%, equal to 28.3% of Group revenues. The decrease vs. Q1'19 is almost entirely due to the one- off cost related to the South African facility.

NET PROFIT: € 37.7 million, -6.6%, equal to 21.6% of Group revenues. The decrease vs. Q1'19 is almost entirely due to the one-off cost related to the South African facility.

NET FINANCIAL POSITION: + € 215.5 million at March 31, 2020, an increase of € 42.6 million compared to € 172.9 million at December 31, 2019.

FREE CASH FLOW: € 39.8 million at March 31, 2020, +11.8% compared to € 35.6 million at March 31, 2019.

LIAISON PLACEMENTS: Q1'20 CLIA net placements equal to +94 units; overall installed base of 8,383 units at March 31, 2020. The reduced number of new placements is due to the Chinese market situation, where pandemic didn't allow to install LIAISON XL platforms in the quarter.

DIASORIN TESTS IN RESPONSE TO COVID-19 PANDEMIC: following COVID-19 pandemic, DiaSorin developed and launched a rapid molecular test in March for use on its LIAISON MDX platform. Starting from a swab, the test allows the detection of the virus within 1.5 hours as opposed to the 6-8 hours of the other available tests. Furthermore, in April, DiaSorin launched a serology test to be run on LIAISON XL platforms for the detection of IgG neutralizing antibodies against the infection. Both tests are CE marked and have received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA).

WITHDRAWAL OF BUSINESS OUTLOOK RELEASED ON MARCH 11, 2020: Company's business outlook released on March 11, 2020 did not reflect the impacts deriving from COVID-19 and therefore cannot remain unchanged. Given the significant deterioration of the macroeconomic scenario and the related market uncertainties caused by the global spread of the pandemic, the high uncertainty on the length and the impact on the Company's results for the current year, DiaSorin believes appropriate to withdraw its 2020 guidance. The Company will provide updates in this regard to the market as greater visibility into the foreseeable evolution of the business increases.

1

Saluggia (Italy), May 13, 2020 - The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), a global leader in the research, production and marketing of diagnostic tests, examined and approved the Q1'20 consolidated economic and financial results.

Q1

change

Amounts in million of euros

%

%

2019

2020

am ount

@ current

@ CER

Revenues

170.8

174.6

+3.9

+2.3%

+1.7%

CLIA tests

113.7

112.6

-1.2

-1.0%

-1.3%

ELISA tests

23.0

20.9

-2.1

-9.2%

-9.8%

Molecular tests

16.2

24.5

+8.3

+51.4%

+47.9%

Instruments sales and other revenues

17.8

16.6

-1.2

-6.6%

-6.6%

EBITDA

67.5

64.5

-3.0

-4.5%

-3.7%

EBITDA margin

39.6%

36.9%

-262 bps

EBIT

53.0

49.4

-3.6

-6.7%

EBIT margin

31.0%

28.3%

-272 bps

Net profit

40.4

37.7

-2.7

-6.6%

COMMENT ON

CONSOLIDATED REVENUES

RESULTS

Revenues: € 174.6 million, +2.3% compared to Q1'19 (+1.7% at CER). Revenue trend influenced by positive molecular diagnostic sales, also driven by the launch of the test for the detection of COVID-19. CLIA sales, net of Vitamin D, increased by 2.8% at CER and were negatively impacted by the strong decrease in sales volumes in China, both in February and March. In March sales volumes showed a downward trend also in Italy, in the U.S. and in some European countries, due to the COVID-19 pandemic. Expected decline in sales of Vitamin D, (heavily impacted by COVID-19) as well as of Elisa tests and instruments.

Foreign exchange rates had a positive impact of about € 1.0 million on Group revenues.

Q1'20 sales trend by technology as follows:

  • CLIA, net of Vitamin D: +2.8% (+2.8% at CER)
  • Vitamin D (CLIA): -12.7% (-13.8% at CER)
  • ELISA tests: -9.2%(-9.8% at CER)
  • Molecular tests: +51.4% (+47.9% at CER)
  • Instruments sales and other revenues: -6.6% (-6.6%at CER)

The expansion of CLIA platforms continued in Q1'20, with net placements of +94 units, reaching an overall total of 8,383 units.

2

Revenues by geography

The following provides the breakdown of the Group consolidated revenues by geographic region.

Q1

Change

Amounts in millions of euros

2019

2020

amount

%

@ current

@ CER

Europe and Africa

82.0

89.5

+7.5

+9.2%

+9.0%

% on total revenues

48.0%

51.3%

USA and Canada

48.9

55.5

+6.6

+13.6%

+10.3%

% on total revenues

28.6%

31.8%

Asia Pacific

30.5

20.2

-10.3

-33.8%

-33.1%

% on total revenues

17.9%

11.5%

Latin America

9.4

9.4

-0.0

-0.2%

+5.8%

% on total revenues

5.5%

5.4%

Total

170.8

174.6

+3.9

+2.3%

+1.7%

Europe and Africa

Revenues in Q1'20 were € 89.5 million, +9.2% (+9.0% at CER) compared to Q1'19.

Sales trend reflected two different dynamics: i) the decline in routine tests volumes in countries reporting early Coronavirus cases (expecially in Italy); ii) the positive contribution from Coronavirus molecular tests' sales and tests' stock piling by some customers who anticipated a negative impact of the pandemic on the distribution and circulation of supplies in Europe.

A breakdown of revenues by country is shown below:

  • Italy: +0.5%,
  • Germany: +20.0%
  • France: -2.0%
  • Export: -1.7%(-2.6% at CER).

USA and Canada

Revenues in Q1'20 were € 55.5 million, +13.6% (+10.3% at CER) compared to Q1'19.

Business in the quarter was affected by a downward trend in sales of CLIA tests starting from March, as a consequence of the spread of Coronavirus in the country. This trend heavily impacted the routine tests menu, particularly Vitamin D.

Molecular diagnostics' sales registered a strong increase, equal to +51.4% (+47.9% at CER), also on the back of the contribution from sales of rapid COVID-19 test, which was made available in the U.S. market following the Emergency Use Authorization from the U.S. Food and Drug Administration on March 20.

Asia Pacific

Revenues in Q1'20 were € 20.2 million, -33.8% (-33.1%at CER) compared to Q1'19.

The region suffered the sharpest decline in revenues during Q1'20, due to the spread of COVID-19 at the end of January, primarily attributable to China where the outbreak emerged first.

A breakdown of revenues by country is shown below:

  • China: -61.1% in local currency
  • Australia: +5.5% in local currency
  • Export: -10.2% at CER

Latin America

Revenues in Q1'20 were € 9.4 million, almost in line with Q1'19, -0.2%(+5.8% at CER).

Sales were not impacted by COVID-19, highlighting a positive business trend in the countries managed through direct sales. This positive trend was offset by lower revenues in the countries where the DiaSorin Group operates through local distributors.

3

Revenues by technology

A breakdown of revenues by country is shown below:

  • Brazil: +18.7% in local currency
  • Mexico: +2.4% in local currency
  • Export: -5.4% at CER

The following provides a breakdown of Group revenues by technology.

Q1

% of revenues contributed

Change

2019

2020

CLIA tests

66.6%

64.5%

-214 bps

ELISA tests

13.5%

12.0%

-151 bps

Molecular tests

9.5%

14.0%

+455 bps

Instruments sales and other revenues

10.4%

9.5%

-90 bps

4

OPERATING PERFORMANCE

GROSS PROFIT

EBITDA

EBIT

FINANCIAL PERFORMANCE

INCOME TAXES

CONSOLIDATED NET PROFIT

CONSOLIDATED

NFP

FCF

BUSINESS

OUTLOOK

The following provides the Group operating performance in Q1'20.

GROSS PROFIT: € 120.7 million; +1.7%, equal to 69.1% of revenues (69.5% in Q1'19).

The slight decrease in profitability is primarily due to a different mix (geography and products) and higher distribution costs, following the negative impact of Coronavirus on transport logistics at the international level.

EBITDA: € 64.5 million; -4.5% (-3.7%at CER), equal to 36.9% of revenues (39.6% in Q1'19).

In Q1'20, DiaSorin recorded a one-off cost of € 3.3 million related to the South African facility (accounted among non-recurring costs), in relation to which the Group initiated the procedures for insurance coverage. Net of this one-off cost, EBITDA would have been € 67.8 million, equal to 38.8% of Group revenues (39.5% at CER, +1.6% vs. Q1'19).

EBIT: €49.4 million -6.7%, equal to 28.3% of revenues (31.0% in Q1'19).

NET FINANCIAL EXPENSES: € 0.4 million, in line with Q1'19.

INCOME TAXES in Q1'20 were € 11.3 million, with a tax rate of 23.0% (23.2% in Q1'19).

CONSOLIDATED NET PROFIT: € 37.7 million, -6.6%, equal to 21.6% of Group revenues (23.7% in Q1'19).

CONSOLIDATED NET FINANCIAL POSITION at 31 March 2020 was positive at € 215.5 million, an increase of € 42.6 million compared to the balance at December 31, 2019.

Group FREE CASH FLOW in Q1'20 was € 39.8 million, up by € 4.2 million (+11.8%) compared to Q1'19.

Company's business outlook released on March 11, 2020 did not reflect the impacts deriving from COVID-19 and therefore cannot remain unchanged. Given the significant deterioration of the macroeconomic scenario and the related market uncertainties caused by the global spread of the pandemic, the high uncertainty on the lenght and the impact on the Company's results for the current year, DiaSorin believes appropriate to withdraw its 2020 guidance. The Company will provide updates in this regard to the market as greater visibility into the foreseeable evolution of the business increases.

***

Mr. Piergiorgio Pedron, the officer in charge of preparing the corporate accounting documents of DiaSorin S.p.A. declares that, pursuant to paragraph 2, Art. 154 bis of the Consolidated Law on Finance, to the best of his knowledge, the accounting information contained in this Press Release corresponds to the documental results, accounting books and records.

For additional information, please contact:

Riccardo Fava

Emanuela Salvini

Corporate Vice President Communication & Investor Relations

Investor Relator

Tel. +39.0161.487988

Tel. +39.0161.487567

riccardo.fava@diasorin.it

emanuela.salvini@diasorin.it

5

CONSOLIDATED INCOME STATEMENT

(Amounts in million of euros)

Q1

Change

2019

2020

amount

%

Net Revenues

170.8

174.6

+3.9

+2.3%

Cost of sales

(52.1)

(54.0)

-1.8

+3.5%

Gross profit

118.6

120.7

+2.0

+1.7%

69.5%

69.1%

-0.4%

Sales and marketing expenses

(34.5)

(36.4)

-1.8

+5.2%

Research and development costs

(11.7)

(12.4)

-0.8

+6.5%

General and administrative expenses

(17.2)

(16.8)

+0.3

-1.8%

Total operating expenses

(63.4)

(65.6)

-2.2

+3.5%

37.1%

37.6%

+0.5%

Other operating income (expense)

(2.3)

(5.6)

-3.3

n.m.

EBIT

53.0

49.4

-3.6

-6.7%

31.0%

28.3%

-2.7%

Net financial income (expense)

(0.4)

(0.4)

+0.0

-0.6%

Profit before taxes

52.6

49.0

-3.6

-6.7%

Income taxes

(12.2)

(11.3)

+0.9

-7.2%

Net result

40.4

37.7

-2.7

-6.6%

EBITDA

(*)

67.5

64.5

-3.0

-4.5%

39.6%

36.9%

-2.6%

CONSOLIDATED BALANCE SHEET

(Amounts in million of euros)

12/31/2019

03/31/2020

Change

Goodwill and intangibles assets

370.3

377.4

+7.1

Property, plant and equipment

128.4

125.8

-2.6

Other non-current assets

34.1

35.5

+1.4

Net working capital

211.0

211.4

+0.4

Other non-current liabilities

(68.0)

(71.1)

-3.1

Net Invested Capital

675.8

679.0

+3.3

Net Financial Position

172.9

215.5

+42.6

Total shareholders' equity

848.6

894.6

+45.9

CONSOLIDATED STATEMENT OF CASH FLOWS

(Amounts in million of euros)

Q1

2019

2020

Cash and cash equivalents at the beginning of the period

73.1

157.6

Cash provided by operating activities

232.7

55.8

Cash used in investing activities

(52.2)

(16.0)

Cash provided/(used) in financing activities

(68.4)

(0.7)

Acquisitions of companies and business operations

(6.9)

-

Net change in cash and cash equivalents before investments in financial assets

105.1

39.2

Divestment/(Investment) in financial assets

(20.7)

(15.7)

Net change in cash and cash equivalents

84.4

23.5

Cash and cash equivalents at the end of the period

157.6

181.1

  1. EBITDA is defined as the "Operating Result", gross of amortization and depreciation of intangible and tangible assets. EBITDA is a measure used by the Company to monitor and evaluate the Group's operating performance and is not defined as an accounting measure in IFRS and therefore shall not be considered an alternative measure for assessing the Group's operating result performance. Since the composition of EBITDA is not regulated by the reference accounting standards, the criterion of determination applied by the Group may not be homogeneous with that adopted by other operators and/or groups and therefore may not be comparable.

6

Disclaimer

DiaSorin S.p.A. published this content on 13 May 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 May 2020 11:24:01 UTC

share with twitter share with LinkedIn share with facebook
Latest news on DIASORIN S.P.A.
06/15DIASORIN S.P.A. : Ex-dividend day for final dividend
FA
06/10DIASORIN S P A : Shareholders' Meeting June 10, 2020
PU
06/10DIASORIN S.P.A. : Proxy Statments
CO
06/03DIASORIN S P A : The LIAISON® SARS-COV-2 S1/S2 IgG test received the approval fo..
PU
05/18DIASORIN S P A : The liaison® sars-cov-2 s1s2 igg test is the first to receive t..
PU
05/13GLOBAL MARKETS LIVE: Uber sets its sight on GrubHub, Tesla victorious in Cali..
05/13DIASORIN S P A : Fatturato in crescita e redditività confermata nel primo trimes..
PU
05/13DIASORIN S.P.A. : 1st quarter results
CO
05/03Roche wins U.S. nod for COVID-19 antibody test, aims to boost output
RE
04/23Italy's Triboo starts selling Chinese COVID-19 antibody tests
RE
More news
Financials
Sales 2020 869 M 979 M 979 M
Net income 2020 226 M 254 M 254 M
Net cash 2020 289 M 325 M 325 M
P/E ratio 2020 42,1x
Yield 2020 0,75%
Capitalization 9 367 M 10 549 M 10 541 M
EV / Sales 2019
EV / Sales 2020 10,4x
Nbr of Employees 1 950
Free-Float 40,3%
Chart DIASORIN S.P.A.
Duration : Period :
DiaSorin S.p.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DIASORIN S.P.A.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 7
Average target price 152,64 €
Last Close Price 171,00 €
Spread / Highest target 12,6%
Spread / Average Target -10,7%
Spread / Lowest Target -29,8%
EPS Revisions
Managers
NameTitle
Carlo Rosa Chief Executive Officer, Executive Director & GM
Gustavo Denegri Chairman
Piergiorgio Pedron Chief Financial Officer & Senior Corporate VP
Chen Menachem Even Executive Director & Chief Commercial Officer
Franco Moscetti Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
DIASORIN S.P.A.48.18%10 549
BIOMÉRIEUX58.16%16 651
AUTOBIO DIAGNOSTICS CO., LTD.60.20%9 402
10X GENOMICS, INC.15.41%8 656
GUANGZHOU WONDFO BIOTECH CO.,LTD95.65%4 909
MACCURA BIOTECHNOLOGY CO.LTD113.01%4 529